This week’s Case Highlight explores management considerations for advanced disease and associated treatment challenges with Dr. Juanita Crook, Dr. Andrea Apolo and Dr. Charles Peyton.
Explore more clinical cases and discussions in the BackTable App: https://t.co/AQpm7ueBHY
#Urology #UrologicOncology #PenileCancer #MedEd
New NMIBC therapies mean higher patient volumes and more complexity. Is your clinic ready? On the latest collab episode with @_backtableUro, @BogdanaSchmidt, @AmyLuckenbaugh, and Meredith Donahue, DNP/APP, break down how to build a co-managed intravesical therapy clinic. Discover how they manage a 50-patient instillation day, tackle J-code hurdles, and coordinate with pharmacy teams to optimize patient outcomes.
Listen now: https://t.co/dy32qywsX3
This podcast is supported by an educational grant from Johnson & Johnson.
#Urology #BladderCancer #URO306 #HealthcareOperations #ONC63
What matters most to patients when making treatment decisions for non-muscle invasive bladder cancer?
In this cross over episode with BackTable Urology, Dr. Kelly Bree, Meredith Donahue, NP, Dr. Saum Ghodoussipour, and Dr. Vignesh Packiam discuss shared decision-making in NMIBC, including treatment selection, recurrence risk, quality of life considerations, and navigating conversations around escalation or de-escalation of care.
Listen now on BackTable App: https://t.co/6x1Licuf1j
#BladderCancer #NMIBC #UrologicOncology #MedEd #ONC65 #URO308
How do we decide which intermediate-risk prostate cancer patients need treatment intensification? Dr. Ruchika Talwar and Dr. Udit Singhal explore the clinical utility of the one biomarker test and its role in driving decisions around ADT and salvage therapy. While PSMA PET scans offer anatomical detail, genomic testing provides the biological insights necessary for truly personalized care.
Watch the full episode here: https://t.co/nR1WgrFDTe
This podcast is supported by Veracyte.
#URO301 #ProstateCancer #Biomarkers #GenomicTesting
Testing rates are still lagging in prostate cancer, but treatment decisions increasingly depend on getting the genetics right.
Dr. Evan Yu and @TDorffOnc join @alantanmd to discuss germline and somatic testing, BRCA2-driven treatment strategies, PARP inhibitors, and the shift toward biology-based prostate cancer care.
This podcast is supported by an educational grant from Pfizer.
🎧 Listen: https://t.co/h58RRusVgz
#URO307 #ProstateCancer #GeneticTesting #UroOnc
Treatment decisions in penile cancer often require careful consideration of multiple therapeutic approaches.
This week’s Case Highlight explores T2 penile cancer, including brachytherapy options and treatment considerations, with Dr. Juanita Crook and Dr. Charles Peyton.
Explore more clinical cases and discussions in the BackTable App: https://t.co/hAIQSSCNLN
#Urology #UrologicOncology #PenileCancer #MedEd
Can a genomic test tip the scales between surveillance and treatment? Dr. Ruchika Talwar and Dr. Udit Singhal discuss how biomarker tests are shaping risk-adapted management, highlighting both the opportunities and the limitations of current molecular testing. The doctors also highlight practical considerations and discuss real-world cases.
Watch the full episode here:
https://t.co/nR1WgrFDTe
This podcast is supported by Veracyte.
#URO301 #ProstateCancer #Biomarkers #GenomicTesting
What comes after BCG failure?
@UroCancerMD joins @RuchikaTalwarMD to discuss treatment options, emerging therapies, and practical decision-making for patients with BCG-unresponsive NMIBC.
Check out the full episode in the BackTable app: https://t.co/HNvahWP2A0
This podcast is supported by ImmunityBio.
#URO305 #BladderCancer #NMIBC #BCG #UrologicOncology
This week’s Case Highlight focuses on management considerations for high-grade recurrent UTUC with Dr. Jeannie Hoffman-Censits and Dr. Nirmish Singla.
Explore more clinical cases and discussions in the BackTable App: https://t.co/hF85F4VaYe
#Urology#UrologicOncology#UTUC #MedEd
Can genomic data, not just PSA or MRI, guide your next prostate cancer treatment plan? Dr. Ruchika Talwar and Dr. Udit Singhal discuss biomarker tests and how they can supplement traditional testing strategies to reveal hidden molecular heterogeneity, inform prognosis, and predict treatment response in real-world practice.
Watch the full episode here:
https://t.co/nR1WgrGbIM
This podcast is supported by Veracyte.
#URO301 #ProstateCancer #Biomarkers #GenomicTesting
Optimizing office workflows can improve both patient satisfaction and procedural efficiency in OAB care.
Dr. Michael Kennelly and @Jason_Kim_MD join @PReyblat to discuss Botox workflows, PTNS scheduling, Medicare LCD documentation, and reducing no-shows in urology practice.
This podcast was developed in collaboration with @sufuorg.
#URO304 #OAB #Urology #SUFU
https://t.co/bN55dXHshi
What do you do when upper tract cytology is positive but both imaging and ureteroscopy are negative? In this clip, Drs. Vignesh Packiam, Mark Tyson, and Sarah Psutka debate surveillance versus intervention and discuss cystectomy considerations after multiple failed bladder-sparing therapies.
This podcast is supported by Ferring Pharmaceuticals.
#URO277 #Urology #UrologicOncology #NMIBC #BladderCancer
Did you know clinical cases are available in the BackTable App?
This week’s featured discussions include penile cancer imaging preferences, biopsy considerations, and lymph node dissection with Dr. Juanita Crook and Dr. Charles Peyton.
Explore more cases and discussions in the BackTable App: https://t.co/Cl7FzT0lN0
#Urology #UrologicOncology #PenileCancer #MedEd
Really enjoyed hosting this @BackTableUrology discussion with @neerajaiims and @azadoncology on PARP inhibitor management in advanced prostate cancer.
What makes conversations like this so valuable are the candid clinical pearls you rarely hear during podium presentations or see on slides — the real-world nuances of anemia management, fatigue, GI toxicity, dose modifications, molecular testing, and how to actually keep patients on therapy long enough to benefit.
This is the kind of practical experience that directly impacts day-to-day patient care. #mCRPC #PARPinhibitors #GUOnc #ProstateCancer
Successful PARP inhibitor therapy often depends on keeping patients on treatment long enough to benefit.
@neerajaiims and @azadoncology join @alantanmd to discuss anemia, GI toxicity, fatigue management, molecular testing, and practical strategies for PARP inhibitor therapy in advanced prostate cancer.
#URO303 #ProstateCancer #mCRPC #PARPInhibitors
https://t.co/bV2zFW11Q2
When patients fail multiple lines of bladder-sparing therapy, how aggressively should you search for hidden disease? In this clip, Drs. Vignesh Packiam, Mark Tyson, and Sarah Psutka discuss evaluating sanctuary sites, repeat staging, and managing difficult cases like prostatic urethral CIS.
This podcast is supported by Ferring Pharmaceuticals.
#URO277 #Urology #UrologicOncology #NMIBC #BladderCancer
This week’s case highlight 👇
UTUC: Recurring Low-Grade UTUC in a 66-Year-Old with Dr. Jeannie Hoffman-Censits and Dr. Nirmish Singla.
Watch the full case exclusively in the BackTable app: https://t.co/0dSIg0KW3z
#Urology#UroOncology#UTUC#UrothelialCarcinoma
Kicking off the @AmerUrological#YoungUrologists Forum with a well-deserved recognition of @AmyLuckenbaugh who is proof that women really can do it ALL! A gifted surgeon, healer, leader, mom, friend and the @SES_AUA Young Urologist of the Year 😍🎉
Behind the scenes of the #AUA26 “Who to Follow” list 📸🎥
Turns out getting urologists to all look at the same camera at the same time is harder than most procedures we do 😅 Great group and a lot of fun putting this together! @AmerUrological